Samina Vaziralli, 

During FY19, Cipla’s revenue grew 7.5% to ₹16,362 crore and profit by 8.3% to ₹1,528 crore. But Vaziralli, a third-generation scion at Cipla, wants to go beyond medicines and offer healthcare management options to its patients. Her focus is on ensuring that Cipla plans for the next leg of growth. That involves identification of new growth markets like China and taking its partnership model in biosimilars to as many patients around the world as possible. She also plans to move up the value chain by deepening its specialty product pipeline in the U.S. through synergised assets in the respiratory, CNS, and hospital businesses.